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Abstract 
Objective: Aim of this study was to evaluate the impact of HIV-1 very low level viremia (<50 
copies/ml) on the 2-year risk of virological failure. 
Methods: A retrospective analysis including HIV-positive patients presenting two consecutive 
HIV RNA below 50 copies/mL (outpatient clinic in Italy, first semester of 2010) was performed. 
HIV RNA was measured through real time Polymerase Chain Reaction (PCR) assay CAP/CTM 
HIV-1 version 2.0 (detection limit: 20 copies/mL) and stratified as undetectable RNA (“Target 
Not Detected”, TND), <20 copies/mL, 20-50 copies/mL. After 96 weeks virological failure was 
defined as two consecutive viral loads above 50 copies/mL. Log-rank tests and a multivariate Cox 
proportional hazard model were used for uni- and multivariate analysis. 
Results: 1055 patients (71.4% male, 87.4% Caucasian, aged 46.7 years) were included: nadir and 
current CD4 cell count were 203 cells/mm3 (106-292) and 554 cells/mm3 (413-713.5). HIV RNA 
was undetectable in 781 patients (74%), <20 copies/mL in 190 patients (18%) and 20-50 
copies/mL in 84 patients (8%). Virological failure was observed in 81 patients (7.7%); at 
multivariate analysis detectable RNA at baseline (p=0.017), HCV infection (p=0.020), more than 
3 pills in the regimen (p=0.003) and duration of HIV RNA<50 copies/mL below 2 years 
(p<0.001) were independently associated with virological failure. In 14 patients newly selected 
resistance-associated mutations were observed. 
Conclusions: Undetectable HIV RNA by real-time PCR is significantly associated with a lower 2-
year risk of virological failure along with Ab HCV-negativity, longer viral control and lower pill 
burden. Studies investigating the management of residual viremia under antiretroviral treatment 
are warranted. 
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Introduction 
Highly Active Antiretroviral Treatment (HAART) dramatically affects HIV viral replication and 
immune recovery in HIV-positive patients; nevertheless low-level viremia can be detected in 
patients on long-term successful treatment [1,2]. The concepts of residual viremia and of very low 
level viremia (vLLV) has been introduced following the development of highly sensitive methods 
able to detect as few as one copy/mL and the widespread use of commercial tests with increasingly 
lower limits of detection below 50 copies/mL (40, 37 and 20 copies/mL) [3]. Although the exact 
source of residual HIV RNA is still debated [4], it has been associated with possible indicators of 
viral reservoirs size (T lymphocyte CD4+ cell count at nadir, pre-treatment HIV-1 RNA and 
quantitative cell-associated HIV proviral DNA) and with the duration of viral suppression on 
HAART [5-7]. Several studies suggested that the administration of NNRTIs (and specifically 
nevirapine) is associated with the lowest residual viremia [8,9]: the drug target (pre-integration) or 
the penetration into sanctuary sites have been advocated as possible explanations of this observation 
[10]. 
Although the exact impact of vLLV in the long-term management of HIV is poorly understood, two 
aspects have been studied. Both the presence of low-level replication and the aforementioned 
associated factors have been linked to higher levels of immune activation, pro-inflammatory 
cytokines and microbial translocation [11]. Moreover, the possible role of vLLV in predicting later 
virological rebounds has been investigated in a few heterogeneous studies [1,12-18]: with one 
exception [18] all found that having higher levels of residual HIV RNA was associated with an 
increased risk of further virological rebound. In the first published study [17], commercial real-time 
PCR with a cut off of 48 copies/mL was used, but commercial assay with lower HIV RNA cut off 
values are currently available in the clinical setting.  
Therefore, we investigated the determinants and the virological outcome of patients with very low 
level viremia measured by a commercial assay with a limit of quantification of 20 copies/mL in the 
clinical setting. 
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Primary objective of this study was to evaluate the impact of very low level viremia (HIV 
RNA below 50 copies/mL) on the 2-year risk of virological failure in HAART-effectively 
treated patients. Secondary objectives were the analysis of determinants of undetectable 
RNA at baseline and the evaluation of virological consequences after virological failure. 
 
Materials and Methods 
Study design 
A retrospective analysis was performed on all patients followed at a large outpatient clinic in Italy 
(Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Ospedale 
Amedeo di Savoia, ASLTO2) presenting two consecutive HIV RNA below 50 copies/mL in the 
first semester of 2010, the more recent one was considered as baseline virale load. Patients 
with at least 6 months of regular follow up were included. This retrospective study was approved 
by local Ethics Committee and written informed consent was obtained by patients currently in 
care. Data are routinely collected every three months and treatment switches were made according 
to clinicians’ independent decision. 
 
Virological analysis 
HIV RNA was measured through the real time Polymerase Chain Reaction (PCR) assay 
CAP/CTM HIV-1 vs. 2.0 (CAP/CTM, Roche Molecular System, Branchburg, NJ,	  detection limit: 
20 copies/mL of HIV-1 RNA). Patients’ viremia levels were stratified according to three different 
intervals: undetectable RNA (“Target Not Detected”, TND), <20 copies/mL, 20-50 copies/mL. 
The result of HIV RNA measurement below 50 copies/mL was available to clinicians. Genotypic 
Sensitivity Score (GSS) was calculated using cumulative genotypic resistance tests and through 
the Stanford algorithm [19]. GSS was considered equal to the number of administered 
antiretrovirals in patients with unavailable genotypic resistance tests and no history of virological 
failures. Genotypic resistance testing was performed in all virological failures using the standard 
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direct full-population sequencing from plasma samples ViroSeq HIV-1 genotyping (Abbott, IL, 
US). Briefly, after nucleic acid extraction with the semi-automatic NucliSENS easyMAG platform 
(BioMerieux, Marcy l’Etoile, F) from 1 mL of plasma, sequences of HIV-1 protease (P) and 
reverse transcriptase (RT) regions were constructed for each sample with seven different primers 
targeting the majority of HIV-1 P and RT genes. To enhance the sensitivity for samples with HIV-
RNA <1000 copies/mL, the standard ViroSeq HIV-1 protocol was modified in that a nested PCR 
step was introduced. Three Amplicons generated from PCR were visualized on 1% agarose gel 
and sequenced on the ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, Foster City, 
CA, USA) according to the manufacturer’s instruction [20]. Sequence data were assembled and 
analysed with the ViroSeq HIV-1 Genotyping System software 2.7 for the identification of drug-
resistance mutations. Stanford Drug Resistance Database (http://hivdb.stanford.edu) and the 
International AIDS Society, USA drug-resistance mutation list were used to interpret protease and 
reverse transcriptase-resistance mutations [19]. 
 
Definition of failure 
Virological failure was defined as two consecutive viral loads above 50 copies/mL (at least seven 
days apart) or one value above 50 copies/mL in patients lost to follow up. 
 
Statistical analysis 
Normally distributed variables were described with means (±standard deviation, SD) and analyzed 
with parametric testing while not normally distributed ones were described with medians (inter-
quartile ranges, IQR) and analyzed with non-parametric tests. Kaplan-Meier analysis was used to 
estimate the cumulative incidence of virologic failure, stratified according to 3 different exposure 
statuses: TND, <20 copies/mL, 20-50 copies/mL.  
The impact of variables on the risk of virological failure was estimated through Log-rank tests 
and multivariate Cox proportional hazard model. This analysis was performed separately in 
	   7	  
patients who maintained the same regimen for the 2-year observation period (“non-switchers”) as 
well as in all included patients: this was done with the aim of controlling for possible treatment 
switches guided by the presence of low-level HIV RNA. The association of determinants with 
undetectable baseline RNA was estimated through univariate tests (Chi-square, Mann-Whitney) 
and a multivariate binary logistic regression analysis. All multivariate models included variables 
with p values below 0.10 at univariate analysis and backward elimination (variables included in 
the model are detailed in the text). Data analysis was performed using SPSS software for 
Macintosh (version 20.0, IBM Corp.).  
 
Results 
Baseline characteristics 
1055 patients were included in the study: baseline demographic, immunovirological and 
therapeutic characteristics are described in Table 1. Most of the patients were male (753, 71.4%), 
Caucasians (922, 87.4%) and median age was 46.7 years (41.3-53.1); co-infection with HCV was 
present in 295 subjects (28%). Median duration of current antiretroviral treatment (ART) and of 
viral load suppression were 23.7 months (14-40.6) and 39.7 months (20.3-73.1), respectively; HIV 
RNA was constantly below 50 copies/mL since at least 2 years in 705 (66.8%) subjects. Current 
CD4 cell count was 554 cells/mm3 (413-713.5); 513 (48,6%) patients had a nadir below 200 
CD4/mm3.  
Antiretroviral regimens were mostly (85.2%) based on the association of two NRTIs plus either a 
PI [433 patients, 41%: mostly atazanavir/ritonavir (220, 50,8%) followed by lopinavir/ritonavir 
(114, 26,3%) and darunavir/ritonavir (35, 8%)], a NNRTI [424 patients (40,2%), mostly efavirenz 
(238, 56,1%) and nevirapine (150, 35,4%)] or raltegravir (42 patients, 4%). Tenofovir disoproxil 
fumarate was the most commonly administered NRTI (751, 71,2%, in 706 patients co-formulated 
with emtricitabine). Most of the patients were treatment-experienced (940 patients, 89%): 
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genotypic resistance tests were available in 371 subjects (35,1%) and they were used to obtain 
GSS score [(≥3 in 815 patients (77.3%)].  
 
Baseline viral strata and associated factors 
HIV RNA was undetectable in 781 patients (74%), below 20 copies/mL in 190 patients (18%) and 
between 20 and 50 copies/mL in 84 patients (8%).  
The prevalence of baseline viral load strata according to antiretroviral regimen (all patients) and to 
third compound (in patients receiving 2 NRTIs plus a third drug, n=865) is depicted in Figure 1a, 
1b. Paired comparisons highlighted a significantly higher TND prevalence in patients receiving 
NRTIs-only or NN-based regimens as compared to PI-recipients (p=0.007) but not to raltegravir-
recipient (p=0.75); nevirapine recipients showed the highest prevalence (85.1%). Using ANOVA 
tests several significant differences were noted among regimen groups as for CD4 cell count, CD4 
cell nadir, duration of HIV infection and duration of controlled viremia (for instance NNRTIs and 
NRTIs-only recipient had the highest duration of HIV RNA suppression). 
At univariate analysis, variables associated with TND were: age (for 10 years increase, p=0.049), 
female gender (p=0.003), nadir CD4 above 200 cells/mm3 (p=0.002), duration of viral suppression 
above 2 years (p=0.039), the use of ARV regimens consisting of less than 4 pills (p=0.03), the use 
of NNRTIs or raltegravir (p=0.007).  
At multivariate logistic regression analysis (including age, pill count and NNRTI or raltegravir 
use) female gender (p=0.002, aOR 1.68, 95%CI 1.20-2.35), nadir CD4 cell count above 200/mm3 
(p=0.002, aOR 1.56, 95%CI 1.18-2.08) and viral suppression above 2 years (p=0.026, aOR 1.40, 
95%CI 1.04-1.89) were independently associated with TND. 
 
Virological outcome and associated factors 
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After 24 months of follow up, 102 patients were lost, but in 94 (92,2%) of them last available viral 
load was below 50 copies/mL. 860 subjects (81,5%) were still receiving the same baseline 
antiretroviral regimen (“non-switchers”); reasons for treatment switches are available in a minority 
of subjects only. Virological failure was observed in 81 patients (7.7%) with median HIV-RNA 
of 1057 (98-25552) copies/mL; HIV-RNA at failure was between 50 and 200 copies/mL or 
above 200 copies/mL in 31 and 50 patients, respectively.  In the non-switcher group 23 patients 
presented a virological failure (11,8%); HIV-RNA was undetectable in 632 patients (59.9%), <20 
copies/mL in 240 patients (22.7%) and 20-50 copies/mL in 182 patients (17.3%). 2-year median 
CD4 cell count was 572 cells/mm3 (IQR 419-736). 
At univariate analysis detectable RNA at baseline (p=0.003), female gender (p=0.043), HCV 
infection (p=0.004), GSS score below 3 (p=0.007), more than 3 pills (p<0.001), current use of PI-
based regimens (p=0.002) and duration of viral suppression below 2 years (p<0.001) were 
associated with virological rebound. At multivariate analysis (including gender, GSS below 3, PI 
use) detectable RNA at baseline (p=0.017, aOR 1.71, 95%CI 1.10-2.68), HCV infection (p=0.020, 
aOR 1.69, 95%CI 1.08-2.62), more than 3 pills (p=0.003, aOR 1.97, 95%CI 1.26-3.06) and duration 
of viral suppression below 2 years (p<0.001, aOR 2.47, 95%CI 1.58-3.86) were independently 
associated with virological failure. Kaplan Meier curves according to baseline factors are 
represented in Figure 2 (a-d). 
In non-switchers the same variables were identified as independent predictor of virological failure: 
HCV infection (p=0.03, aOR 2.19, 95%CI 1.30-3.68), more than 3 pills (p=0.003, aOR 1.79, 95 IC 
1.21-2.65), duration of viral suppression below 2 years (p<0.001, aOR 2.99, 95%CI 1.75-5.10) and 
detectable RNA at baseline (p=0.018, aOR 1.91, 95%CI 1.12-2.65). 
We assigned an arbitrary score of 1 to the significant predictors of virological failure: a score from 
0 to 4 was therefore calculated. Stratifying patients with low score (0-1) and high score (2-4) was 
significantly associated with the rate of virological failure during follow up (Log rank p <0.001) 
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(Figure 3a and 3b): the absolute risk of virological rebound was 4.5% vs. 13.7% in the low-risk and 
high-risk groups.  
 
Virological outcome at rebound 
Among 73 patients not lost to follow up, 23 patients (31.5%) reported a self-performed treatment 
interruption (Table 2). In 37 (out of 50, 74%) adherent subjects in care at the end of follow up 
genotype resistance testing was successful; median (and interquartile range) HIV RNA was slightly 
lower than in those with unsuccessful genotype test [88 copies/mL (63-440 vs. 1497 copies/mL (76-
5112), Mann-Whitney p=0.10]. 
14 patients (28%) selected new resistance-associated mutations. Characteristics both at baseline and 
at virological failure are summed up in Table 3: most of newly selected mutations were in the 
reverse transcriptase gene (10/14) or in the integrase gene (4 out of 6 raltegravir recipients). In 2 
patients (out of 2 treated with maraviroc-containing regimens) a switch to X4-tropic viruses was 
observed.  
 
Discussion 
Our retrospective analysis on a large sample of HIV-positive patients confirms that the 
undetectability of HIV RNA is associated with a lower risk of virological rebound in the following 
two years of follow up as compared to other two degrees of low level viremia (less than 20 
copies/mL and between 20 and 50 copies/mL). Besides this virological marker a durable control of 
viral replication (above two years), the absence of HCV co-infection and a limited number of pills 
may lower the risk of virological failures. Although seven papers have been published on the 
subject our research may add to current knowledge the use of a low but commercially available 
threshold, the inclusion of patients on raltegravir-containing regimens, the analysis of other factors 
associated with outcome and the characterization of resistance-associated mutations at failure 
[1,12,14-18]. 
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Some limitations should be highlighted: the retrospective design, the absence of a formal evaluation 
of adherence, the already reported intrassay variability in HIV RNA quantification at low viremia 
[21,22]. However, the use of commercial assays with high sensitivity and low limit of detection (20 
copies/mL in this study) is widespread and the “target not detected” output (suggesting HIV RNA 
undetectability) may be relevant in the long-term management of HIV-positive patients. 
The main objective of this study was to assess the impact of the level of viremia below 50 
copies/mL on the risk of virological rebound after two years of follow up: 7.7% of the included 
subjects had a confirmed elevation of plasma viral load. We observed that patients presenting a 
TND at baseline had the lowest incidence of viral rebound in the follow up. The observation that 
patients with the lowest residual viremia had the lowest risk of subsequent virological failures has 
already been reported in several studies [1, 12-17]. However some differences are worthy of being 
mentioned. The study by Doyle and coll. is the only one using the “target not detected” output and 
they showed that this was the group with the best virological outcome [12]. Furthermore, difference 
in follow-up (from 12 to 30 months), definition of low level viremia (persistent versus non-
persistent), different HIV RNA cut offs (50, 48, 40, 27, 3 copies/mL) and methodological issues are 
noteworthy [23-25]. The aforementioned technical differences may partially explain some of the 
observed differences in study outcomes: the CAP/CTM assay vs. 2.0 was associated with a better 
estimation of low-level viremia as compared to Abbott Real Time assay [22,26].  Two reports were 
not concordant with these observations: one had a short follow up and the extended study showed a 
roughly four-fold risk of viral failure among patients with residual viremia [15,16]. The second 
study by Charpentier and coll. using the CAP/CTM vs. 2.0 assay reported an association of 
persistent low level viremia with a higher blip ratio but not on the risk of virological rebound [18].  
Other factors have been identified as being independently associated with virological rebound: 
HCV co-infection, a short (less than 2 years) HIV RNA suppression and the use of antiretroviral 
regimens containing more than three pills. Patients co-infected with HCV may have multiple 
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comorbidities and polypharmacy, immune-dysfunction and possibly incomplete adherence to 
medications [27]; however a detrimental effect of HCV-infection on the durability of HIV control 
has seldom being reported [28]. A prolonged control of HIV replication may be beneficial in 
decreasing reservoir size as well as immune activation and it has been suggested as one of the 
possible factors associated with virological rebound after switching to a boosted protease inhibitor 
regimen [29]. Despite the fact that residual viremia may persist even after seven years of successful 
antiretroviral treatment the risk of viral failure declines with the duration of suppression regardless 
of patients’ adherence [2]. One critical issue would be measuring patients’ adherence to 
medications and it has been recently reported [30]: even if this was not available in this study we 
used pill number as a surrogate marker for adherence, although previous studies showed mixed 
results [31]. It has been shown that higher degrees of compliance to medications are obtained in 
patients receiving easy regimens composed of few pills and possibly once a day: in this scenario the 
use of single tablet regimen has been associated with optimal efficacy results as well as less 
hospitalization and mortality [32]. Regimens including 4 or more pills were associated with a 
higher risk of virological rebound. Beside worse adherence to complex therapies other 
reasons might explain this finding since PI-containing regimens include at least 3 pills: they 
are associated with worse tolerability, less forgiveness (given their short half-lives) and are 
usually administered to patients harboring pre-treated viruses. No difference in virological 
failure was observed between QD and BID treatments: despite discordant results a recent 
large randomized trial suggested that a twice-daily administered but excellently tolerated 
regimen was superior to once-daily PI-based combinations [33].  
In the whole cohort newly selected mutations have been observed in 14 patients only (out of 50 
patients with virological failure and successful viral genotype). The characteristics of the 14 
patients losing future treatment options are described in Table 3 and they confirm the chance of 
selecting RAMs in patients treated with drugs with low (NNRTIs or raltegravir) or undefined 
(maraviroc) genetic barrier to resistance [34].  
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Combining these factors into a simple score (arbitrary assigning a 1 point to each of these variables, 
also taking into account the similarities in adjusted odds ratio of the multivariate model) may 
provide a clinical useful model. Stratifying patients according to the presence of 0 or 1 factor (low 
risk) or 2 or more (high-risk) factors was associated with a significant ability to discriminate 
patients with low or high chance of ensuing viral rebound (4.5% vs. 13.7%). Once confirmed in 
prospective independent cohorts this score may be relevant for allocating patients to less 
frequent monitoring or less-drug regimens [35]. 
These data, may suggest that the optimal target of antiretroviral treatment may be lowered (as it 
happened in the past with the availability of more sensitive tests) to the achievement of undetectable 
RNA. Nevertheless the management of low level viremia is currently unknown and it deserves 
prospective clinical studies. Intensification studies of conventional HAART to determine the 
contribution of ongoing viral replication to residual viremia have shown heterogeneous results: 
while Yukl et al. found a decrease of unspliced HIV RNA in the ileum (but not in plasma, PBMCs, 
duodenum, colon or rectum) [36] other authors found no effect [37-46]. 
It is noteworthy that none of these studies included the use of nevirapine: the drug has been 
associated with the lowest residual viremia in two studies [8,9] and with long term control of 
HIV viremia in a dual therapy with raltegravir [47]. Despite some unfavourable 
characteristics (hepatotoxicity, skin rashes, low genetic barrier to resistance) that placed 
nevirapine among alternative regimens in international guidelines, favourable 
pharmacokinetic features and tolerability may support prospective switch studies using 
nevirapine-containing regimens. 
One of the secondary objective of this study was the analysis of the variables associated with the 
HIV RNA undetectability (TND) using the Taqman 2.0 test: 74% of long-term efficaciously treated 
HIV-positive patients presented an undetectable HIV RNA. We found that female gender, high 
nadir CD4 cell count and durable HIV RNA suppression were independently associated with TND. 
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While gender differences have not been definitively demonstrated [48,49] both CD4 nadir and 
durable viral replication control have been associated with low reservoir size, less residual viremia 
and less immune-activation [50-52]. At univariate analysis we also found that both NNRTI-based 
and raltegravir-based regimens had the highest prevalence of TND as compared to PI-based, NRTI-
sparing and complex regimens; surprisingly 81.5% of patients taking 3 or 4 NRTIs (with no other 
antiretrovirals) had a not detectable RNA. The groups of patients with different antiretroviral 
regimens showed significantly differences in CD4 nadir and HIV RNA suppression and the 
treatment-related effect disappeared at the multivariate analysis: these baseline disparities as well as 
the inclusion of the number of pills (indirectly linked to patients’ adherence to medication) may 
explain this observation. However in patients under “conventional regimens” i.e. those receiving 
two NRTIs plus a third drug, nevirapine and raltegravir recipients showed the highest rates of TND: 
while the favorable association between nevirapine use and low residual viremia has already been 
reported [8,9] such raltegravir effect is a novel observation. Raltegravir mechanism of action, 
activity in macrophages and very fast viral decay as well as the long-term excellent efficacy and 
tolerability may explain this finding [53]. The discovery of other possible reservoirs (such as CD4-
associated) [54-56] or lymph nodes [57-59] remains essential for the goal of HIV functional cure: 
pharmacological properties of antiretroviral compounds may justify some of these observations 
(and favoring drugs with higher tissue distribution such as nevirapine) [23]. 
 
In conclusion, having an undetectable RNA, more than 2 years of HIV RNA below 50 copies/mL, 
being HCV-free and being treated with less than 4 pills were associated with a lower 2-year risk of 
virological rebound in the following two years of follow up. The majority (74%) of patients with 
confirmed HIV-1 RNA below 50 copies/mL present no detectable RNA using a 20 copies/mL 
commercially available real-time PCR assay. Female gender, nadir CD4 cell count above 
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200/mm3 and viral suppression above 2 years were independently associated with TND at 
baseline. 
 These data warrant further investigation in the context of the management of low-level viremia in 
HIV-positive treated patients. 
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